Search Results - "Roccia, T."

Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study by Loriot, Y., Necchi, A., Park, S.H., Huddart, R.A., Burgess, E., Zhong, B., Santiago-Walker, A., Little, S., Roccia, T., De Porre, P., Siefker-Radtke, A.O.

Get full text

P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY by Einsele, H., Dhakal, B., Schecter, J. M., Roccia, T., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Connors, K., Qi, K., Londhe, A., Carson, R., Voelker, J., Cost, P., Valluri, S., Florendo, E., Pacaud, L., Yong, K.

Get full text

B09 CARTITUDE‐2 COHORT B 18‐MONTH FOLLOW‐UP: CILTACABTAGENE AUTOLEUCEL (CILTA‐CEL), A BCMA‐DIRECTED CAR‐T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY by Zweegman, S., Agha, M., Cohen, A.D., Cohen, Y.C., Anguille, S., Kerre, T., Roeloffzen, W., Madduri, D., Schecter, J.M., De Braganca, K.C., Jackson, C.C., Varsos, H., Mistry, P., Roccia, T., Xu, X., Li, K., Zudaire, E., Corsale, C., Akram, M., Geng, D., Pacaud, L., Sonneveld, P., Donk, N.

Get full text

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA‐CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON‐CELLULAR ANTI‐B‐CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY by Donk, N., Mateos, M.‐V., Cohen, Y.C., Rodriguez‐Otero, P., Paiva, B., Cohen, A.D., Martin, T., Suvannasankha, A., Madduri, D., Corsale, C., Schecter, J.M., De Braganca, K.C., Jackson, C.C., Varsos, H., Deraedt, W., Roccia, T., Mistry, P., Xu, X., Li, K., Zudaire, E., Akram, M., Pacaud, L., Avivi, I., San‐Miguel, J.

Get full text

P960: HEALTH‐RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL‐LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by Delforge, M., Moreau, P., Einsele, H., De Stefano, V., Lindsey‐Hill, J., Vincent, L., Mangiacavalli, S., Perrot, A., Ocio, E., Seldam, S., ’. Groen‐Damen, E. I., Semerjian, M., Strulev, V., Schecter, J. M., Roccia, T., Gries, K. S., Nesheiwat, T., Wapenaar, R., Mateos, M.‐V., Weisel, K.

Get full text

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE‐REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1‐3 PRIOR LINES OF THERAPY: CARTITUDE‐2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA by Hillengass, J., Cohen, A. D., Delforge, M., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M.‐S., Scheid, C., Schecter, J. M., De Braganca, K. C., Varsos, H., Yeh, T.‐M., Mistry, P., Roccia, T., Corsale, C., Akram, M., Pacaud, L., Nesheiwat, T., Agha, M., Cohen, Y. C.

Get full text

S185: CARTITUDE‐2 COHORT B: UPDATED CLINICAL DATA AND BIOLOGICAL CORRELATIVE ANALYSES OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY by Agha, M. E., Donk, N. W., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W., Schecter, J. M., De Braganca, K. C., Varsos, H., Mistry, P., Roccia, T., Zudaire, E., Corsale, C., Akram, M., Geng, D., Nesheiwat, T, Pacaud, L., Sonneveld, P., Zweegman, S.

Get full text

P958: REAL‐LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY by Einsele, H., Moreau, P., De Stefano, V., Dytfeld, D., Angelucci, E., Benjamin, R., Goldschmidt, H., Donk, N. W., Besemer, B., Scheid, C., Vij, R., ’. Groen‐Damen, E. I., Semerjian, M., Strulev, V., Schecter, J. M., Roccia, T., Nesheiwat, T., Wapenaar, R., Weisel, K., Mateos, M.‐V.

Get full text

Multiple BM harvests in pediatric donors for thalassemic siblings: safety, efficacy and ethical issues by Biral, E, Chiesa, R, Cappelli, B, Roccia, T, Frugnoli, I, Noè, A, Soliman, C, Fiori, R, Cursi, L, Cattaneo, F, Evangelio, C, Miniero, R, Ciceri, F, Roncarolo, M G, Marktel, S

“…Allogeneic BMT represents the only chance of cure for β-thalassemia. Occasionally, two affected individuals from the same family share a matched healthy…”
Get full text

920TiPErdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study by Loriot, Y, Necchi, A, Park, S H, Huddart, R A, Burgess, E, Zhong, B, Santiago-Walker, A, Little, S, Roccia, T, De Porre, P, Siefker-Radtke, A O

Get full text

Optimal thalassaemia-free survival and minimal regimen-related toxicity in 50 consecutive high-risk beta thalassaemia paediatric patients using myeloablative therapy with intravenous busulphan by Chiesa, R, Cappelli, B, Crocchiolo, R, Biral, E, Noe, A, Frugnoli, I, Roccia, T, Evangelio, C, Fossati, M, Ciceri, F, Roncarolo, M.G, Marktel, S

“…Busulfan(Bu), associated with Cyclophosphamide(Cy), is part of standard conditioning regimen prior to stem cell transplantation(SCT) in beta…”
Get full text

Thiotepa-cyclophosphamide high-dose immunosuppressive therapy with autologous haematopoietic stem cell transplantation in aggressive forms of multiple sclerosis: results in 9 patients by Roccia, T, Corti, C, Bernardi, M, Peccatori, J, Bonini, C, Comi, G, Radaelli, M, Ciceri, F, Moiola, L, Stanghellini, M.T. Lupo, Greco, R

“…Background: Autologous stem cell transplantation (ASCT) has been performed for aggressive Multiple Sclerosis (MS) with raising frequency; standard…”
Get full text

Cyclosporine neurotoxicity in beta-thalassaemic children undergoing myeloablative BMT by Noe, A, Marktel, S, Chiesa, R, Evangelio, C, Frugnoli, I, Fossati, M, Biral, E, Napolitano, S, Ferrua, F, Biffi, A, Roccia, T, Rocarolo, M.G, Ciceri, F, Cappelli, B

“…Severe neurotoxicity (tremors, insomnia, agitation, headache, hallucinations, seizures, cortical blindness, aphasia and ataxia) is a recognized complication of…”
Get full text

Escalating doses of donor lymphocytes to rescue from rejection following bone marrow transplantation for thalassaemia by Frugnoli, I, Cappelli, B, Chiesa, R, Noe, A, Biral, E, Gattillo, S, Roccia, T, Evangelio, C, Fossati, M, Napolitano, S, Giardelli, A, Soliman, C, Ciceri, F, Roncarolo, M.G, Marktel, S

“…Mixed chimerism (MC) and secondary graft failure are frequent events following BMT for thalassemia. There is limited information regarding the outcome of donor…”
Get full text

Management of platelets transfusions in highly immunised beta thalassaemia children undergoing bone marrow transplantation by Napolitano, S, Zino, E, Chiesa, R, Cappelli, B, Crocchiolo, R, Biral, E, Noe, A, Frugnoli, I, Roccia, T, Evangelio, C, Fossati, M, Polselli, A, Barzizza, L, Rossini, S, Ciceri, F, Ronchi, P, Roncarolo, M.G, Fleischhauer, S, Marktel, S

“…Between 2005 and 2008, 47 thalassemia patients from middle east countries received a Bu-Cy based myeloablative BMT in our unit. During the aplasia post BMT, we…”
Get full text